PDL BioPharma (PDLI) Says Roche to Discontinue Joint Agreement to Develop and Commercialize Daclizumab
Tweet Send to a Friend
PDL BioPharma, Inc. (Nasdaq: PDLI) announced that Roche will discontinue its agreement with PDL to jointly develop and commercialize daclizumab ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
